SARA MICHELLY GONCALVES BRANDAO

(Fonte: Lattes)
Índice h a partir de 2011
5
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina
LIM/11 - Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Resultados de Busca

Agora exibindo 1 - 10 de 21
  • article 4 Citação(ões) na Scopus
    Defining Characteristics of Decreased Cardiac Output: A Literature Review
    (2011) BRANDAO, Sara Michelly Goncalves; ALTINO, Denise Meira; SILVA, Rita de Cassia Gengo e; LOPES, Juliana de Lima
    OBJECTIVE. The study aims to proceed a literature review of defining characteristics (DCs) of decreased cardiac output (DCO). METHODS. Medline database was used to perform this study. The descriptors used were ""low cardiac output"" and ""nursing diagnosis."" RESULTS. Seventy-nine DCs were identified. Among them, 28 have already been approved by NANDA-I. Some data from microcirculation assessment such as high levels of serum lactate and decreased oxygen venous saturation were identified as indicators of this nursing diagnosis. CONCLUSIONS. Some of the approved DCs were identified through literature review but others seem to be new as they have not been cited in the NANDA-I classification. PRACTICAL IMPLICATIONS. Further content and clinical validations are needed to confirm if data from microcirculation might be considered as DCs of DCO.
  • conferenceObject
    Use of proliferation signal inhibitors in heart transplantation
    (2013) SAMUEL, M. Avila; BISELLI, B.; ULHOA JUNIOR, M. B.; NUSSBAUM, A. Santos; ESCALANTE, J. P.; MERCONDES-BRAGA, F. G.; AYUB-FERREIRA, S. M.; BRANDAO, S. M.; BACAL, F.; BOCCHI, E. A.
  • conferenceObject
    Plasma Biomarkers Reflecting High Oxidative Stress Predicts Myocardial Injury Related to Anthracycline Chemotherapy in the CECCY Trial
    (2018) WANDERLEY JR., Mauro R.; AVILA, Monica S.; FERNANDES-SILVA, Miguel M.; CUNHA-NETO, Edecio; CRUZ, Fatima D.; BRANDAO, Goncalves Sara M.; RIGAUD, Vagner O.; HAJJAR, Ludhmila A.; KALIL FILHO, Roberto; BOCCHI, Edimar A.; AYUB-FERREIRA, Silvia M.
  • conferenceObject
    Circulating miR-1 And miR-133b Correlate With Subclinical Myocardial Injury In Breast Cancer Patients Under Doxorubicin Treatment
    (2015) OLIVEIRA-CARVALHO, Vagner; FERREIRA, Ludmila R.; BORGES, Danielle P.; AYUB-FERREIRA, Silvia M.; AVILA, Monica S.; BRANDAO, Sara M.; CRUZ, Fatima; CUNHA-NETO, Edecio; BOCCHI, Edimar A.
  • conferenceObject
    Cost-effectiveness of long-term disease management program in heart failure: results from the REMADHE trial
    (2013) BOCCHI, E. A.; CRUZ, F.; BRANDAO, S.; GUIMARAES, G.; BACAL, F.; ISSA, V. S.; CHIZZOLA, P.; SOUZA, G.; FERREIRA, S. M. A.
  • article 0 Citação(ões) na Scopus
    Treatment of fungal infection on left ventricle assist device driveline exit site: a case report and systematic review
    (2023) BRANDAO, Sara Michelly Goncalves; BISELI, Bruno; AYUB-FERREIRA, Silvia Moreira; STRABELLI, Tania Mara Varejao; BOCCHI, Edimar Alcides
    Objective: The use of ventricular assist devices (VAD) is increasing; however, diagnosis and management of device complications, such as the driveline exit site (DES) being the portal of entry for fungal infection, is not well known. Method: A systematic review involving searching PubMed (2005 to July 2020) was conducted. The case of a 43-year-old female patient who had a left VAD (LVAD) (HeartMate 3, Abbott, US) is also reported. Results: The patient was successfully treated with ketoconazole cream and oral fluconazole for likely superficial DES fungal infections. We included 36 studies that met our inclusion criteria; however, only one was included in our review. In the literature, five cases of DES fungal infection were reported, with Candida being the only fungal pathogen. Conclusion: LVAD fungal infections are uncommon but can be responsible for high mortality rates, require a prolonged period of treatment, and can present a huge problem when surgical alternatives are not available. However, Candida species are most common. Fungal infections can only produce clear discharge, and so the classic definition of driveline infection based on purulent secretion can vary. Negative skin culture does not exclude the diagnosis of infection of the DES, and so empirical diagnosis may only be clinically based.
  • conferenceObject
  • conferenceObject
    CARVEDILOL FOR PREVENTION OF CHEMOTHERAPY-INDUCED CARDIOTOXICITY: FINAL RESULTS OF THE PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CECCY TRIAL
    (2020) AYUB-FERREIRA, Silvia M.; AVILA, Monica; BRANDAO, Sara; CRUZ, Fatima D.; WANDERLEY JR., Mauro; RIGAUD, Vagner O. C.; HAJJAR, Ludhmila; KALIL-FILHO, Roberto; CRUZ, Cecilia B. V.; ALVES, Marco Stephan; GUIMARAES, Guilherme V.; ABDUCH, Maria; ISSA, Victor S.; SANTOS, Marilia; BITTENCOURT, Marcio; BOCCHI, Edimar Alcides
  • article 8 Citação(ões) na Scopus
    Cost-Effectiveness Benefits of a Disease Management Program: The REMADHE Trial Results
    (2018) BOCCHI, Edimar Alcides; CRUZ, Fatima das Dores da; BRANDAO, Sara Michelly; ISSA, Victor; AYUB-FERREIRA, Silvia Moreira; ROCCA, Hans-Peter Brunner la; WIJK, Sandra Sanders van
    Background: Published studies have generated mixed, controversial results regarding the Cost-effectiveness of heart failure disease management programs (HF-DMPs). This study assessed the cost-effectiveness of an HF-DMP in ambulatory patients compared with usual care (UC). Methods: In the prospective randomized REMADHE trial, we evaluated incremental costs per quality adjusted life-year (QALY) and life-year (LY) gained as effectiveness ratios (ICERs) over a study period of 2.47 +/- 1.75 years. Results: The REMADHE HF-DMP was more effective and less costly than UC in terms of both QALYs and LYs (95% and 55% chance of dominance, respectively). Average saving was US$7345 (2.5%-97.5% bootstrapped confidence interval similar to 16,573 to +921). The chance of DMP being cost-effective at a willingness to pay US$10,000 per QALY or LY was 99% and 96%, respectively. Cost-effectiveness of HF-DMP was highest in subgroups with left ventricular ejection fraction <35%, age >50 years, male sex, New York Heart Association (NYHA) functional class >= III, and ischemic etiology. The chance of DMP being cost-effective at a willingness to pay US$10,000 per QALY was >= 90% in all subgroups apart from NYHA functional class I-II, where it was 70%. Even when the intervention costs increased by 500% or when excluding outliers in costs, DMP had a high chance of being cost-effective (87%-99%). Conclusions: The HF-DMP of the REMADHE trial, which encompasses long-term repeated education alongside telephone monitoring, has a high probability of being cost-effective in ambulatory patients with HF.
  • article 15 Citação(ões) na Scopus
    Comparative cost-effectiveness of surgery, angioplasty, or medical therapy in patients with multivessel coronary artery disease: MASS II trial
    (2018) BRANDAO, Sara Michelly Goncalves; REZENDE, Paulo Cury; ROCCA, Hans-Peter Brunner-La; JU, Yang Ting; LIMA, Antonio Carlos Pedroso de; TAKIUTI, Myrthes Emy; HUEB, Whady; BOCCHI, Edimar Alcides
    BackgroundThe costs for treating coronary artery disease (CAD) are high worldwide. We performed a prespecified analyses of cost-effectiveness of three therapeutic strategies for multivessel CAD.MethodsFrom May 1995 to May 2000, a total of 611 patients were randomly assigned to coronary artery bypass graft (CABG), n=203; percutaneous coronary intervention (PCI), n=205; or medical treatment (MT), n=203. This cost analysis study was based on the perspective of the Public Health Care System. Initial procedural and follow-up costs for medications, cardiology examinations, and hospitalizations for complications were calculated after randomization. Life-years and quality-adjusted life years (QALYs) were used as effectiveness measures. Incremental cost-effectiveness ratios (ICER) were obtained by using nonparametric bootstrapping methods with 5000 resamples.ResultsInitial procedural costs were lower for MT. However, the subsequent 5-year cumulative costs were lower for CABG. Compared with baseline, the three treatment options produced significant improvements in QALYs. After 5years, PCI and CABG had better QALYs results compared with MT. The ICER results favored CABG and PCI, and favored PCI over CABG in 61% of the drawings. On the other hand, sensitivity analysis showed MT as the preferred therapy compared with CABG and PCI, in the analysis considering higher costs.ConclusionsAt 5-year follow-up, the three treatment options yielded improvements in quality of life, with comparable and acceptable costs. However, despite higher initial costs, the comparison of cost-effectiveness after 5years of follow-up among the three treatments showed both interventions (CABG and PCI) to be cost-effective strategies compared with MT.Trial registration ISRCTN, ISRCTN66068876, Registered 06/10/1994, http://www.controlled-trials.com/ISRCTN66068876